Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T21:34:44.865Z.
Calculation as of: 2026-10-06T21:34:44.865Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 148236961db35e193d1d700acaf87b22991c3a1a7f0bfa22e817431605aef681
PEG RATIO
N/A
Zhengye Biotechnology Holding Limited
Market Cap
$52.60M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Zhengye Biotechnology Holding Limited (ZYBT) | $52.60M | N/A |
| Spectral AI, Inc. (MDAI)vs › | $52.83M | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.99M | N/A |
| ImageneBio Inc (IMA)vs › | $51.88M | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.70M | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A |
| Tenax Therapeutics, Inc. (TENX)vs › | $51.19M | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $54.14M | N/A |
| biote Corp. (BTMD)vs › | $50.28M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
